 annie 
Miembro
Registrado: Octubre 2005
Mensajes: 5055
Ubicación: Madrid.España
Patologia: Mieloma estadio 1 con TMO autologo en 1996..actualmente en RC
Tipo usuario: paciente
Nombre Real: Muriel-Annie.
Pais: españa
|
 SmartBrief IMFIndividualizing Treatment Of Patients With Mye
he leido estas noticias en SmartBrief(IMF)
cita.
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
" J Clin Oncol. 2008 Apr 21
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents.
San-Miguel J, Harousseau JL, Joshua D, Anderson KC.
Servicio de Hematología, Hospital Universitario de Salamanca (Centro de Investigación del Cáncer–Instituto de Biología Molecular del Centro del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas) Salamanca, Spain; University Hospital Nantes, Nantes, France; Institute of Hematology, Royal Prince Alfred Hospital, Sidney, Australia; and the Dana-Farber Cancer Institute, Boston, MA.
Progress in the understanding of multiple myeloma (MM) cell biology has led to the identification of new relevant prognostic factors and subsequently different risk groups. This concept, together with the recent discovery of new drugs with novel mechanisms of action, will probably lead to individualized treatment according to the different patients' characteristics. In this review, we focus on current available agents already approved for MM, and discuss individualized treatment approaches for both transplantation candidates (subdivided into standard and high-risk patients) and elderly patients. Future progress in MM will be based on using science to inform the design of the optimal combined treatments, and high throughput assays that can assess the ability of combination therapies to induce death of MM cells, both alone and in the bone marrow microenvironment."
|
Foro 
